Floatz logo

Capecitabine

Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Chongqing University Cancer HospitalSmall moleculePhase 2Active
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Extensive Stage Small Cell Lung Cancer (ES-SCLC) cohort.

Asset / SponsorPhaseRating
hs-20093
Shanghai Hansoh Biomedical Co., Ltd
Phase 3BB
Ide-161
IDEAYA Biosciences
Phase 1CC

Same molecule, other indications

Capecitabine is also rated in:

Locally Advanced Rectal CancerDormant
BBB
Indicative ·
75 / 100
View asset →
colorectal neoplasmDormant
BBB
Indicative ·
74 / 100
View asset →
rectal carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →